Intellia Therapeutics on Wednesday set the terms for its planned initial public offering, saying it will sell 5 million shares at $16 to $18 a pop. The gene editing company has applied to list its common stock on the Nasdaq exchange under the ticker symbol "NTLA", it said in a regulatory filing. Credit Suisse, Jefferies, Leerink Partners and Wedbush PacGrow are underwriters on the deal. Intellia focuses on developing proprietary therapeutics using a recently developed biological tool, according to its prospectus.
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below